Vanguard Global Advisers »

Celldex Therapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $826k 26k 31.72

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Celldex Therapeutics

Wellington Management Company
Kynam Capital Management
BlackRock
FMR
Vanguard Group
Bellevue Group
State Street Corporation
Point72 Asset Management
Vanguard Capital Management
Commodore Capital
Geode Capital Management
Eventide Asset Management
Eversept Partners
Braidwell
Deep Track Capital

View all funds holding Celldex Therapeutics